Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure?

Carlo Buonerba, Michele Caraglia, Simona Malgieri, Francesco Perri, Davide Bosso, Piera Federico, Matteo Ferro, Mimma Rizzo, Giovannella Palmieri, Giuseppe Di Lorenzo

Research output: Contribution to journalArticle

Abstract

Denosumab has been proven to be at least as effective with respect to zoledronic acid in preventing skeletal-related events in patients with bone metastases from solid tumors. Although denosumab can be considered to have a more favorable toxicity profile compared to zoledronic acid in terms of kidney toxicity and flu-like symptoms, hypocalcemia is twice as frequent with denosumab. Importantly, denosumab is not metabolized by the kidney and it may be employed even in patients with severe kidney failure. Like zoledronic acid, denosumab is administered with oral calcium and vitamin D. As conversion of vitamin D to its active form is progressively impaired with a creatinine clearance <70 ml/min, we speculate that calcitriol may be a better option than vitamin D in denosumab-treated patients with impaired kidney function.

Original languageEnglish
Pages (from-to)149-151
Number of pages3
JournalExpert Opinion on Biological Therapy
Volume13
Issue number2
DOIs
Publication statusPublished - Feb 2013

    Fingerprint

Keywords

  • bone metastasis
  • calcitriol
  • denosumab
  • zoledronic acid

ASJC Scopus subject areas

  • Pharmacology
  • Clinical Biochemistry
  • Drug Discovery

Cite this

Buonerba, C., Caraglia, M., Malgieri, S., Perri, F., Bosso, D., Federico, P., Ferro, M., Rizzo, M., Palmieri, G., & Di Lorenzo, G. (2013). Calcitriol: A better option than vitamin D in denosumab-treated patients with kidney failure? Expert Opinion on Biological Therapy, 13(2), 149-151. https://doi.org/10.1517/14712598.2012.756470